Showing results (11-20 of 119) with videos related to
Sort By:
Pageof 12
Drugs|December 15, 2010
The potential role of B cell-targeted therapies in multiple sclerosisAaron Boster, Daniel P Ankeny, Michael K RackeExpert Review of Neurotherapeutics|August 26, 2011
What happens when natalizumab therapy is stopped?Stephen M Schaaf, David Pitt, Michael K RackeJournal of Neurochemistry|August 31, 2007
Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosisJihong Xu, Michael K Racke, Paul D DrewFrontiers in Neurology|January 31, 2022
Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical VignettesMichael K Racke, Elliot M Frohman, Teresa FrohmanPPAR Research|July 8, 2008
PPAR-gamma: Therapeutic Potential for Multiple SclerosisPaul D Drew, Jihong Xu, Michael K RackeTrends in Immunology|June 1, 2005
PTX cruiser: driving autoimmunity via TLR4Michael K Racke, Wei Hu, Amy E Lovett-RackeClinical Neuropharmacology|February 2, 2018
Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis CenterBrett Alldredge, Allison Jordan, Jaime Imitola, et al.Biochimica Et Biophysica Acta|July 6, 2010
Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?Amy E Lovett-Racke, Yuhong Yang, Michael K RackeJournal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 2, 2014
Is T-bet a potential therapeutic target in multiple sclerosis?Michael K Racke, Yuhong Yang, Amy E Lovett-RackeNeurology. Clinical Practice|November 1, 2013
Multiple sclerosis: Five new thingsJacqueline A Nicholas, Aaron L Boster, Michael K RackePageof 12